Pharmaceutical Supply Chain Transparency: What DSCSA Means for Clinics

Pharmaceutical supply chain transparency means every prescription drug package can be traced from its manufacturer to your clinic. Under the DSCSA, that comes down to transaction records, serialized product identifiers, licensed trading partners, and fast lot-level recall response. USA MedPremium, a licensed wholesale distributor in Fort Lauderdale, Florida, ships Rx orders with DSCSA records.

For a clinic, transparency isn't an abstract industry goal. It decides whether you can prove where a vial came from, answer a state inspector, and pull the right lot off your shelf the day a recall is announced. This guide explains what the Drug Supply Chain Security Act (DSCSA) requires, what changed with the enhanced requirements, and how to check that your suppliers are holding up their end.

What the DSCSA Requires: The Paper Trail Behind Every Package

Congress passed the DSCSA in 2013 as Title II of the Drug Quality and Security Act. It builds an electronic, interoperable system to identify and trace most finished prescription drugs at the package level as they move from manufacturer to wholesale distributor to dispenser. The law's definition of dispenser covers pharmacies and other persons authorized by law to dispense or administer prescription drugs, which can include clinics and medical practices.

Each time ownership of a covered product changes hands, the seller passes product tracing information to the buyer:

• Transaction information (TI): the product name, strength, dosage form, NDC, container size, number of containers, lot number, transaction date, shipment date, and the business names and addresses of the seller and buyer.
• Transaction statement (TS): the seller's attestation that it is authorized under the DSCSA, received the product from an authorized trading partner, received TI and a TS from the prior owner, and did not knowingly ship a suspect or illegitimate product.
• Transaction history (TH): the older ownership chain back to the manufacturer. FDA notes that section 582(k)(1) effectively ended the requirement to provide and receive TH starting November 27, 2023, but trading partners still need systems to gather tracing information back to the manufacturer when FDA or a state official asks during a recall or investigation.

Dispensers must capture this information and keep it for at least six years after the transaction, so your receiving process is part of your compliance program, not just your supplier's.

Serialization: The Product Identifier on Each Package

Manufacturers and repackagers put a product identifier on each package and homogeneous case of covered product. It includes the NDC, a unique serial number, the lot number, and the expiration date, encoded in a 2D data matrix barcode with human-readable text. Serialization is what lets a single package be matched to its transaction records instead of an entire shipment.

For clinics, the practical point is simple: if a package looks wrong, has a damaged or missing barcode, or doesn't match the paperwork, the product identifier is what you, your distributor, and the manufacturer use to verify whether it's legitimate.

The Enhanced Requirements and Where Exemptions Stand

The enhanced drug distribution security requirements took effect November 27, 2023. From that point, trading partners are generally required to exchange TI and TS through secure, interoperable electronic systems, include package-level product identifiers, verify product at the package level, and respond promptly to recall and investigation requests. FDA then set a one-year stabilization period through November 27, 2024 to help trading partners finish their systems.

After that, FDA issued time-limited exemptions for groups of trading partners. The one most relevant to small practices covers small business dispensers, meaning the company that owns the dispenser has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians. In August 2026, FDA extended that exemption to November 27, 2027. It lets qualifying small dispensers and their trading partners keep using current methods for certain electronic exchange and package-level verification requirements, but it doesn't waive the rest of the DSCSA.

Exemption status changes, so check FDA's current exemptions page rather than relying on a supplier's summary, and ask your distributor how it will send records under each scenario.

Verifying Trading Partners Before You Order

The DSCSA requires every trading partner to be authorized: wholesale distributors must hold a valid state license (or FDA license where a state doesn't license) and report licensure to FDA each year. Buying from an unauthorized source is the most common way illegitimate product reaches a clinic.

• Look up the distributor's license with the state agency that issued it. In Florida, prescription drug wholesale distributor permits are issued by the Department of Business and Professional Regulation (DBPR) and searchable on its license search.
• Use FDA's list of state licensing agencies to check out-of-state distributors and third-party logistics providers.
• Confirm the name and address on the license match the invoice and the ship-from address.
• Ask how the distributor sends TI and TS, and get a sample before your first Rx order.

Our guide on how to qualify a pharmaceutical distributor walks through the full checklist, and the Florida DSCSA distributor checklist covers state-specific steps.

Lot Traceability, Suspect Product, and Recalls

Lot numbers in your TI are what turn a recall notice into a five-minute shelf check instead of a full inventory count. Record lot and expiration at receiving, keep them with the stock location, and file the TI and TS where staff can find them.

If a product is suspect, for example it has a mismatched label, an altered package, or came from an unexpected source, quarantine it and contact your distributor to investigate. If it's determined to be illegitimate, the DSCSA requires notifying FDA and appropriate immediate trading partners within 24 hours, using Form FDA 3911. FDA's drug recalls page lists current recalls.

A Clinic Transparency Checklist

• Buy Rx only from distributors you've verified as authorized trading partners.
• Receive TI and TS with every covered Rx shipment, electronically where required.
• Keep tracing records for at least six years and make them retrievable by lot.
• Check that package barcodes, lots, and expiration dates match the paperwork at receiving.
• Write down your quarantine and FDA notification steps for suspect product.
• Recheck FDA's exemption status each year, especially if you rely on the small dispenser exemption.

How USA MedPremium Supports Transparency

USA MedPremium is a licensed pharmaceutical and medical-supply wholesale distributor based in Fort Lauderdale, Florida. Our current state licenses are listed on our pharmaceutical licensing page, so you can verify them at the source. We send DSCSA transaction information and transaction statements with Rx shipments, and our compliance team credentials every buyer before Rx ordering opens.

If you're setting up wholesale purchasing for the first time, see how licensed clinics purchase Rx wholesale. USA MedPremium does not sell controlled substances.

Related reading:

• How to Qualify a Pharmaceutical Distributor
• Best DSCSA-Compliant Distributors for Florida Clinics
• How Licensed Clinics Purchase Prescription Drugs Wholesale
• How to Verify a LegitScript / BBB Medical Wholesaler

Sources

• FDA: Drug Supply Chain Security Act (DSCSA)
• FDA: Title II of the Drug Quality and Security Act (DSCSA statute)
• FDA: DSCSA product tracing requirements (FAQ)
• FDA guidance: DSCSA Standards for the Interoperable Exchange of Information for Tracing
• FDA: DSCSA compliance policies establish 1-year stabilization period
• FDA: Exemptions under the DSCSA (small dispensers until Nov 27, 2027)
• FDA: Check licensure of wholesale drug distributors and 3PLs
• FDA: Notify FDA of illegitimate products (Form FDA 3911)
• FDA: Drug recalls
• Florida DBPR: License search